Polycythemia Vera

American Family Physician

Volumn 69, Issue 9, 2004, Pages 2139-2144+2146

  Stuart, Brian J ^a,b   Viera, Anthonty J ^a,c  

^a NAVAL HOSPITAL JACKSONVILLE   (United States)

^b Group Aid Station   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ALPHA2B INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; CYPROHEPTADINE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FEXOFENADINE; HEMOGLOBIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; HYDROXYZINE; HYDROXYZINE EMBONATE; PAROXETINE; PHOSPHORUS 32; PIPOBROMAN; RECOMBINANT ALPHA2B INTERFERON; TERFENADINE;

ALOPECIA; ANEMIA; ANOREXIA; AUTOIMMUNE DISEASE; BLOOD OXYGEN TENSION; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CHRONIC LUNG DISEASE; CONFUSION; DEPRESSION; DIARRHEA; ERYTHROCYTOSIS; ERYTHROMELALGIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; INSOMNIA; KIDNEY DISEASE; LEG ULCER; LEUKEMIA; LEUKOPENIA; LIVER VEIN OBSTRUCTION; LUNG FIBROSIS; MOUTH ULCER; NAIL DISEASE; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHLEBOTOMY; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PRURITUS; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SKIN ULCER; SMOKING; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WEIGHT REDUCTION;

HUMANS; POLYCYTHEMIA VERA;

EID: 2342608933     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003;78:174-94.
2. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
3. Lamy T, Devillers A, Bernard M, Moisan A, Grulois I, Drenou B, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997;102:14-20.
4. Hoffman R. Hematology: basic principles and practice. 3d ed. New York: Churchill Livingstone, 2000:1130-55.
5. Tefferi A. Diagnosing polycythemia vera: a paradigm shift. Mayo Clin Proc 1999;74:159-62.
6. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36(1 Suppl 2):9-13.
7. Polycythemia: primary and secondary. In: Kjeldsberg CR. Practical diagnosis of hematologic disorders. 3d ed. Chicago: ASCP Press, 2000:121.
8. Berlin NI. Polycythemia vera: diagnosis and treatment 2002. Expert Rev Anticancer Ther 2002;2:330-6.
9. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995;89:748-56.
10. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001;38(1 Suppl 2):21-4.
11. Grover SA, Barkun AN, Sackett DL. The rational clinical examination. Does this patient have splenomegaly? JAMA 1993;270:2218-21.
12. Weinberg RS, Worsley A, Gilbert HS, Cuttner J, Berk PD, Alter BP. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk Res 1989;13:331-8.
13. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the thrombocythemia vera study group. Semin Thromb Hemost 1997;23:339-47.
14. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
15. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haemat 2001;115:619-21.
16. Fruchtman SM, Wasserman LR. Therapeutic recommendations for polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:337.
17. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997;23:441-54.
18. Gilbert HS. Current management in polycythemia vera. Semin Hematol 2001;38(1 Suppl 2):25-8.
19. Barbui T, Finazzi G. Treatment of polycythemia vera. Haematologica 1998;83:143-9.
20. Polycythemia vera: the natural history of 1213 patients followed for 20 Years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995;123:656-64.
21. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002;99:1144-9.
22. Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma 2000;36:239-53.
23. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol 2000;79:103-9.
24. Silver RT. Interferon alpha-2b: a new treatment for polycythemia vera. Ann Intern Med 1993;119:1091-2.
25. Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29(3 Suppl 10):10-5.
26. Physician's desk reference. 58th ed. Montvale, N.J.: Thomson PDR, 2004.
27. Klasco RK, ed. USP DI drug information for the healthcare professional. Greenwood Village, Colo.: Thomson Micromedex, 2004.